Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medical Experiment - Assessment of Efficacy & Safety of Local, Targeted Therapy With Neuropeptide Labelled With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) as Supplementary Therapy in Glioma (WHO G3-G4) Progression

NCT06975332 is registered in ClinicalTrials.gov with Medical University of Warsaw as lead sponsor.

NCT NCT06975332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06975332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medical Experiment - Assessment of Efficacy & Safety of Local, Targeted Therapy With Neuropeptide Labelled With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) as Supplementary Therapy in Glioma (WHO G3-G4) Progression
Lead sponsor
Medical University of Warsaw
Phase
Not applicable
Overall status
Recruiting
Start date
October 9, 2024
Completion date
September 30, 2028
Enrollment
35 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, grade iii astrocytoma, grade iii glioma, high-grade gliomas